Published in Pharmacogenet Genomics on May 01, 2016
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA (2009) 6.91
Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet (2009) 6.13
The earliest known eutherian mammal. Nature (2002) 3.48
Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry (2007) 3.26
Prefrontal white matter in pathological liars. Br J Psychiatry (2005) 3.22
High frequencies of de novo CNVs in bipolar disorder and schizophrenia. Neuron (2011) 3.08
Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr Serv (2004) 2.94
Errors in the completion of the death notification form. S Afr Med J (2007) 2.94
Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia. Proc Natl Acad Sci U S A (2007) 2.81
Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am J Hum Genet (2004) 2.71
The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr Bull (2003) 2.67
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry (2005) 2.62
A prospective gait analysis study in patients with diplegic cerebral palsy 20 years after selective dorsal rhizotomy. J Neurosurg Pediatr (2008) 2.23
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev (2011) 2.07
An evaluation of commercial fluorescent bead-based luminex cytokine assays. PLoS One (2008) 2.06
Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr (2011) 1.98
Length distributions of identity by descent reveal fine-scale demographic history. Am J Hum Genet (2012) 1.91
Genetic association and brain morphology studies and the chromosome 8p22 pericentriolar material 1 (PCM1) gene in susceptibility to schizophrenia. Arch Gen Psychiatry (2006) 1.86
Significant improvement of heart function by cotransplantation of human mesenchymal stem cells and fetal cardiomyocytes in postinfarcted pigs. Ann Thorac Surg (2002) 1.84
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry (2007) 1.73
Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia. Neuropsychopharmacology (2007) 1.70
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res (2007) 1.68
Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry (2007) 1.67
Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry (2002) 1.66
Genetic variation in DTNBP1 influences general cognitive ability. Hum Mol Genet (2006) 1.61
Elucidating the relationship between DISC1, NDEL1 and NDE1 and the risk for schizophrenia: evidence of epistasis and competitive binding. Hum Mol Genet (2008) 1.60
Association of genetic variation in the MET proto-oncogene with schizophrenia and general cognitive ability. Am J Psychiatry (2010) 1.58
Interaction between FEZ1 and DISC1 in regulation of neuronal development and risk for schizophrenia. Neuron (2011) 1.57
White matter abnormalities in first-episode schizophrenia or schizoaffective disorder: a diffusion tensor imaging study. Am J Psychiatry (2005) 1.56
Cannabis use disorders in schizophrenia: effects on cognition and symptoms. Schizophr Res (2010) 1.55
Patterns of stress in schizophrenia. Psychiatry Res (2008) 1.55
Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics. CNS Drugs (2007) 1.51
GSTM1 and GSTT1 polymorphisms as modifiers of age at diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) in a homogeneous cohort of individuals carrying a single predisposing mutation. Mutat Res (2006) 1.51
Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry (2014) 1.50
Pharmacogenomic Research in South Africa: Lessons Learned and Future Opportunities in the Rainbow Nation. Curr Pharmacogenomics Person Med (2011) 1.49
Clozapine as a first treatment for schizophrenia. Am J Psychiatry (2003) 1.49
Toward more transparent and reproducible omics studies through a common metadata checklist and data publications. OMICS (2014) 1.49
White matter abnormalities in obsessive-compulsive disorder: a diffusion tensor imaging study. Arch Gen Psychiatry (2005) 1.49
Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry (2003) 1.47
Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes. Br J Psychiatry (2009) 1.47
Association of the DTNBP1 locus with schizophrenia in a U.S. population. Am J Hum Genet (2004) 1.45
Risk factors for psychosis: impaired social and role functioning. Schizophr Bull (2011) 1.43
Cognitive development in schizophrenia: follow-back from the first episode. J Clin Exp Neuropsychol (2006) 1.42
Clinical and cognitive correlates of suicide attempts in bipolar disorder: is suicide predictable? J Clin Psychiatry (2011) 1.42
DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry (2006) 1.41
Runs of homozygosity implicate autozygosity as a schizophrenia risk factor. PLoS Genet (2012) 1.40
No evidence for phenotypic variation between probands in case-control versus family-based association studies of schizophrenia. Am J Med Genet (2002) 1.40
Gray matter structural alterations in psychotropic drug-naive pediatric obsessive-compulsive disorder: an optimized voxel-based morphometry study. Am J Psychiatry (2008) 1.40
Neurocognition as a stable endophenotype in bipolar disorder and schizophrenia. J Nerv Ment Dis (2006) 1.38
The nature of relapse in schizophrenia. BMC Psychiatry (2013) 1.38
Protease inhibitor resistance in South African children with virologic failure. Pediatr Infect Dis J (2009) 1.37
Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr Res (2010) 1.35
D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry (2010) 1.33
High dose D-serine in the treatment of schizophrenia. Schizophr Res (2010) 1.33
Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol (2011) 1.31
Psychometric properties of the Multidimensional Scale of Perceived Social Support in youth. Compr Psychiatry (2007) 1.29
Volume reduction in prefrontal gray matter in unsuccessful criminal psychopaths. Biol Psychiatry (2005) 1.28
Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology (2007) 1.27
White matter development in adolescence: diffusion tensor imaging and meta-analytic results. Schizophr Bull (2012) 1.25
Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol (2012) 1.25
Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther (2008) 1.25
Genome-wide association study of ancestry-specific TB risk in the South African Coloured population. Hum Mol Genet (2013) 1.25
Genome-wide association study implicates NDST3 in schizophrenia and bipolar disorder. Nat Commun (2013) 1.25
Sex differences in frontal lobe white matter microstructure: a DTI study. Neuroreport (2003) 1.23
White matter abnormalities in early-onset schizophrenia: a voxel-based diffusion tensor imaging study. J Am Acad Child Adolesc Psychiatry (2005) 1.23
End of the Beginning and Public Health Pharmacogenomics: Knowledge in 'Mode 2' and P5 Medicine. Curr Pharmacogenomics Person Med (2012) 1.23
Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia. Biol Psychiatry (2006) 1.22
Classification of gastric pit patterns by confocal endomicroscopy. Gastrointest Endosc (2008) 1.21
Antipsychotic drugs and obesity. Trends Mol Med (2010) 1.21
Effects of serotonin transporter promoter polymorphisms on serotonin function. Neuropsychopharmacology (2004) 1.21
DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia. Biol Psychol (2007) 1.21
A schizophrenia risk gene, ZNF804A, influences neuroanatomical and neurocognitive phenotypes. Neuropsychopharmacology (2010) 1.21
Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry (2012) 1.20
DTNBP1 genotype influences cognitive decline in schizophrenia. Schizophr Res (2006) 1.20